Research Analysts Set Expectations for ACRS Q2 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at Wedbush issued their Q2 2025 earnings estimates for Aclaris Therapeutics in a note issued to investors on Wednesday, May 28th. Wedbush analyst M. Fan forecasts that the biotechnology company will earn ($0.12) per share for the quarter. Wedbush has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share. Wedbush also issued estimates for Aclaris Therapeutics' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($1.11) EPS.

Several other analysts have also commented on ACRS. HC Wainwright reissued a "buy" rating and set a $16.00 price target (down from $20.00) on shares of Aclaris Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a report on Tuesday, March 18th. They set an "overweight" rating on the stock. Finally, Scotiabank cut their price objective on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.71.

Aclaris Therapeutics Price Performance

Shares of ACRS stock traded up $0.02 during mid-day trading on Friday, hitting $1.46. 212,320 shares of the stock traded hands, compared to its average volume of 1,186,911. The stock has a market cap of $157.55 million, a P/E ratio of -2.80 and a beta of 0.42. The stock's fifty day moving average is $1.30 and its two-hundred day moving average is $2.16. Aclaris Therapeutics has a 52-week low of $0.99 and a 52-week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Institutional Investors Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. ExodusPoint Capital Management LP acquired a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $26,000. Invesco Ltd. purchased a new position in Aclaris Therapeutics in the 4th quarter valued at $28,000. Graham Capital Management L.P. purchased a new position in shares of Aclaris Therapeutics during the 4th quarter worth $35,000. Commonwealth Equity Services LLC acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth about $36,000. Finally, Alpine Global Management LLC acquired a new position in Aclaris Therapeutics in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 98.34% of the company's stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.